SOURCE-LINKED STUDY SUMMARY
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
What was studied?
A phase 2, double-blind randomized trial tested eloralintide versus placebo for weight management. The primary outcome was percentage bodyweight change at 48 weeks.
What changed?
Mean weight loss was 9%, 12%, 18% and 20% at 1, 3, 6 and 9 mg; escalation groups lost 20% and 16%, versus 0.4% with placebo. Nausea and fatigue were the most common adverse events.
Who was studied?
263 adults aged 18–75 had obesity, or overweight with a weight-related condition, without type 2 diabetes.
Studied exposure
Weekly subcutaneous eloralintide for 48 weeks: 1, 3, 6 or 9 mg, or escalation from 6 to 9 or 3 to 9 mg; comparator: placebo.
What remains uncertain?
Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(25)02155-5